<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988088</url>
  </required_header>
  <id_info>
    <org_study_id>16932</org_study_id>
    <secondary_id>H8H-MC-LAHX</secondary_id>
    <nct_id>NCT03988088</nct_id>
  </id_info>
  <brief_title>A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Pediatric Patients With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is the measure the levels of lasmiditan in the body of children aged
      6 to 17 with migraine. The study also will also examine the safety and tolerability of
      lasmiditan in children aged 6 to 17 with migraine.

      The study will last about 6 weeks, and includes 4 visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Actual">February 24, 2020</completion_date>
  <primary_completion_date type="Actual">January 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan</measure>
    <time_frame>30 Minutes Postdose through 24 Hours Postdose</time_frame>
    <description>PK: Cmax of Lasmiditan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration-Versus-Time Curve (AUC) from Time Zero to Infinity (AUC[0-∞]) of Lasmiditan</measure>
    <time_frame>30 Minutes Postdose through 24 Hours Postdose</time_frame>
    <description>PK: AUC[0-∞] of Lasmiditan</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lasmiditan given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Lasmiditan</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have a history of migraine headaches for more than 6 months

          -  Participants must have a history of 2 to 15 migraine headaches per month in the past 2
             months

          -  Participants must weigh between 15 and 55 kilograms (kg)

          -  Participants must not have a migraine headache on the day of lasmiditan administration

        Exclusion Criteria:

          -  Participants must not be pregnant or nursing

          -  Participants must not have any acute, serious, or unstable medical condition

               -  Participants must not be actively suicidal or at significant risk for suicide, in
                  the opinion of the investigator

          -  Participants must not be on a medicine that acts in the brain and spinal cord
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Perserverance Research Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newport Beach Clinical Research Associates, Inc.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qps-Mra, Llc</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute at Palm Beach Neurology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume Clinical Pharmacology Clinic</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Hospital, Tokyo</name>
      <address>
        <city>Shinjyuku</city>
        <state>Tokyo</state>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children and Women's Hospital- Shipping Location</name>
      <address>
        <city>San Juan</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/migraine/LAHX#?postal=</url>
    <description>A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine</description>
  </link>
  <verification_date>May 1, 2020</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

